MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.25
-0.08
-1.50%
After Hours: 5.83 +0.58 +11.05% 19:08 02/26 EST
OPEN
5.40
PREV CLOSE
5.33
HIGH
5.40
LOW
5.06
VOLUME
189.34K
TURNOVER
--
52 WEEK HIGH
10.50
52 WEEK LOW
4.450
MARKET CAP
146.00M
P/E (TTM)
-2.1070
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-ContraFect Announces Appointment Of Jane F. Barlow To Board Of Directors
reuters.com · 02/11 12:22
ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors
YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threate...
GlobeNewswire · 02/11 12:00
What Kind Of Shareholders Hold The Majority In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Every investor in ContraFect Corporation ( NASDAQ:CFRX ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 12/30/2020 05:55
What Kind Of Shareholders Hold The Majority In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Every investor in ContraFect Corporation ( NASDAQ:CFRX ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 12/30/2020 05:55
What Kind Of Shareholders Hold The Majority In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Simply Wall St. · 12/30/2020 05:55
Is CFRX A Good Stock To Buy Now?
Insider Monkey · 12/11/2020 22:59
Is CFRX A Good Stock To Buy Now?
Insider Monkey · 12/11/2020 22:59
Is CFRX A Good Stock To Buy Now?
Insider Monkey · 12/11/2020 22:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CFRX. Analyze the recent business situations of ContraFect through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CFRX stock price target is 17.75 with a high estimate of 22.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 94
Institutional Holdings: 22.32M
% Owned: 80.27%
Shares Outstanding: 27.81M
TypeInstitutionsShares
Increased
20
1.00M
New
13
345.84K
Decreased
15
297.51K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Chief Executive Officer/Director
Roger Pomerantz
Chief Financial Officer/IR Contact Officer
Michael Messinger
Executive Vice President
Cara Cassino
Vice President - Finance
Nancy Dong
Vice President
Jane Ambler
General Counsel/Secretary
Natalie Bogdanos
Lead Director
Sol Barer
Director
Lishan Aklog
Director
Jane Barlow
Independent Director
David Low
Independent Director
Michael Otto
Independent Director
Cary Sucoff
  • Dividends
  • Splits
  • Insider Activity
No Data
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.